$0.04
(5.02%)
Add to watchlist
Create an alert
Stocks and Shares ISAHeron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.
Company Information
About this company
Key people
Adam Morgan
Chairman of the Board
Craig Alexander Collard
Chief Executive Officer, Director
Ira Duarte
Chief Financial Officer, Executive Vice President
Mark Hensley
Chief Operating Officer, Executive Vice President
William P. Forbes
Executive Vice President, Chief Development Officer
Craig A. Johnson
Lead Independent Director
Tom Cusack
Director
Sharmila Dissanaike
Independent Director
Michael Kaseta
Independent Director
Click to see more
Key facts
- Shares in issue188.54m
- EPICHRTX
- ISINUS4277461020
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$155.56m
- Employees128
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.